Neurology Medical News about malignant glioma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-Oncology, 10/06/09

Quant EC et al. – Those patients with malignant gliomas who progressed despite a bevacizumab–containing regimen rarely responded to the second bevacizumab–containing chemotherapeutic regimen. In such patients, alternate therapies should be considered.

<< Previous
Intraoperative imprint cytology of central neurocytoma: The great...

Next >>
Discordant Nadir GH After Oral Glucose and IGF-I Levels on...

MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09 Relevance Score: 68%

Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09 Relevance Score: 67%

A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma
Anticancer Research, 11/13/09 Relevance Score: 67%

Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
Molecular Cancer Research, 11/06/09 Relevance Score: 67%

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09 Relevance Score: 67%